The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): A pooled analysis of outcomes in the CAPACITY (CAP) studies
C. Albera, W. Bradford, U. Costabel, T. King, P. Noble, S. Sahn, J. Szwarcberg, D. Valeyre, R. du Bois (Turin, Italy; Brisbane, San Francisco, Durham, Charleston, Denver, United States Of America; Essen, Germany; Paris, France)
Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Albera, W. Bradford, U. Costabel, T. King, P. Noble, S. Sahn, J. Szwarcberg, D. Valeyre, R. du Bois (Turin, Italy; Brisbane, San Francisco, Durham, Charleston, Denver, United States Of America; Essen, Germany; Paris, France). The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): A pooled analysis of outcomes in the CAPACITY (CAP) studies. Eur Respir J 2010; 36: Suppl. 54, 389
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: